Physician profile
Martin Slavin
NPI 1508853672
$14,606.08
in general payments reported to CMS, 2019-2025
34 companies · $3,348 in 2025
The $3,348 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $1,397 · 2021: $1,900 · 2022: $1,854 · 2023: $2,518 · 2024: $2,831 · 2025: $3,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,695.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,686.47 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $2,000.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,154.98 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $950.84 | 2020-2025 | Nexletol |
| Gilead Sciences, INC. | $787.42 | 2019-2025 | |
| Amarin Pharma, INC. | $637.69 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $576.42 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $546.28 | 2020-2024 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $447.34 | 2019-2022 | |
| Amgen INC. | $424.90 | 2022-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $396.08 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $378.89 | 2019-2025 | |
| Glaxosmithkline, LLC. | $373.21 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $346.20 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $298.32 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $283.63 | 2024-2025 | Edarbi, Alvesco, Horizant |
| E.R. Squibb & Sons, L.L.C. | $278.33 | 2021-2023 | Eliquis, Camzyos |
| Corium, LLC | $276.18 | 2023-2025 | Azstarys |
| Astellas Pharma US INC | $267.76 | 2019-2024 | Myrbetriq, Veozah |
| Allergan, INC. | $266.16 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $233.95 | 2022-2023 | Rexulti |
| Abbott Laboratories | $200.13 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $191.43 | 2023-2025 | |
| Currax Pharmaceuticals LLC | $125.01 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $122.51 | 2025 | Neffy |
| Cumberland Pharmaceuticals, INC. | $104.71 | 2024-2025 | Kristalose |
| Intra-Sana Laboratories | $64.44 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Arbor Pharmaceuticals, INC. | $43.03 | 2021 | |
| Novartis Pharmaceuticals Corporation | $40.46 | 2019-2023 | |
| Hologic Sales and Service, LLC | $24.30 | 2024 | Aptima |
| Clarus Therapeutics INC. | $23.09 | 2021 | |
| Scilex Pharmaceuticals INC. | $21.76 | 2023 | Ztlido |
| Antares Pharma, INC. | $19.91 | 2020 | |
| Metuchen Pharmaceuticals | $13.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Slavin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.